Impaired corpus luteum function and other undesired results of pregnancies associated with inadvertent administration of a long-acting agonist of gonadotrophin-releasing hormone

1992 ◽  
Vol 7 (4) ◽  
pp. 465-468 ◽  
Author(s):  
Arie Herman ◽  
Raphael Ron-El ◽  
Abraham Golan ◽  
Hana Nachum ◽  
Yigal Soffer ◽  
...  
1986 ◽  
Vol 108 (3) ◽  
pp. 323-328 ◽  
Author(s):  
T. A. Bramley ◽  
G. S. Menzies ◽  
D. T. Baird

ABSTRACT The effects of a number of analogues of gonadotrophin-releasing hormone (GnRH) on the binding of a radiolabelled GnRH agonist (GnRH-A; d-Ser(But)6, des Gly10]GnRH-ethylamide) to homogenates of human corpus luteum (CL) and rat pituitary tissue were compared. Specific binding was inhibited by GnRH and GnRH-like peptides only. Both the C-terminal amide and N-terminal region of the GnRH molecule were required for binding in both tissues. However, amino acid substitutions at position 6 markedly enhanced, and at position 8 markedly reduced, binding potencies in rat pituitary tissue compared with human CL binding sites. These results indicate that GnRH-binding sites of rat pituitary and human luteal tissue have a similar degree of specificity for GnRH-like peptides, and a similar requirement for both N- and C-terminal regions of the peptide, but that differences in specificity related to the mid-chain region of GnRH exist between human luteal and rat pituitary binding sites. J. Endocr. (1985) 000, 000–000


2001 ◽  
Vol 16 (3) ◽  
pp. 492-494 ◽  
Author(s):  
S.F. Yim ◽  
I.H. Lok ◽  
L.P. Cheung ◽  
C.M. Briton-Jones ◽  
T.T.Y. Chiu ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document